SCHEMBL890039

SCHEMBL890039

c1ccc(-c2nnnn2-c2ccccc2)cc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.77
HSD17B10 Q99714 1/20 0.77
ALDH1A1 P00352 8/20 0.74
L3MBTL1 Q9Y468 3/20 0.74
PTGS2 P35354 3/20 0.66
SMN1; SMN2 Q16637 3/20 0.66
PKM P14618 1/20 0.66
TSHR P16473 6/20 0.65
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
MAPK10 P53779 1/20 0.53
MAPT P10636 2/20 0.52
HTT P42858 2/20 0.52
HPGD P15428 1/20 0.52
CCR6 P51684 1/20 0.52
CACNA1B Q00975 1/20 0.52
APBA1 Q02410 1/20 0.52
NPSR1 Q6W5P4 3/20 0.51
RAB9A P51151 1/20 0.51
ALOX15 P16050 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL351809 0.98 LMNA (0.74) LMNAHSD17B10ALDH1A1L3MBTL1PTGS2
Bromide SCHEMBL28098177 0.98 LMNA (0.74) LMNAHSD17B10ALDH1A1L3MBTL1PTGS2
Hydrochloric Acid SCHEMBL7981337 0.98 LMNA (0.74) LMNAHSD17B10ALDH1A1L3MBTL1PTGS2
SCHEMBL11531369 0.90 ALDH1A1 (0.70) LMNAHSD17B10ALDH1A1L3MBTL1PTGS2
Urea SCHEMBL28915393 0.89 PTGS2 (0.64) LMNAHSD17B10ALDH1A1L3MBTL1PTGS2
SCHEMBL11536760 0.89 ALDH1A1 (0.65) LMNAHSD17B10ALDH1A1L3MBTL1PTGS2
SCHEMBL15452507 0.89 ALDH1A1 (0.71) LMNAHSD17B10ALDH1A1L3MBTL1PTGS2
SCHEMBL8534360 0.87 LMNA (0.71) LMNAHSD17B10ALDH1A1L3MBTL1PTGS2
Hydrochloric Acid SCHEMBL5459649 0.87 L3MBTL1 (0.73) LMNAHSD17B10ALDH1A1L3MBTL1PTGS2
SCHEMBL15541266 0.86 ALDH1A1 (0.63) LMNAHSD17B10ALDH1A1L3MBTL1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 300 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105814702-B Curable organosilicon composition and optical semiconductor device 道康宁东丽株式会社 2018-06-26 CN claimed
US-9691951-B2 Curable silicone composition, and optical semiconductor device DOW CORNING TORAY CO., LTD. (JP) 2017-06-27 US claimed
CN-106749070-A New Biphenyltetrazoles derivative and preparation method thereof 北方民族大学 2017-05-31 CN claimed
EP-3059768-A1 CURABLE SILICONE COMPOSITION, AND OPTICAL SEMICONDUCTOR DEVICE Dow Corning Toray Co., Ltd. (JP) 2016-08-24 EP claimed
US-20160233395-A1 Curable Silicone Composition, And Optical Semiconductor Device DOW TORAY CO., LTD. (JP) 2016-08-11 US claimed
CN-101143853-B Biphenyltetrazoles compounds and preparation method thereof UNIV SHENYANG PHARMACEUTICAL 2012-05-16 CN claimed
EP-2001869-A1 PROCESS FOR PRODUCING BIPHENYL-TETRAZOLE COMPOUNDS Ulkar Kimya Sanayii Ve Ticaret A.S. (TR) 2008-12-17 EP claimed
CN-101143853-A Biphenyltetrazoles compounds and preparation method thereof UNIV SHENYANG PHARMACEUTICAL (CN) 2008-03-19 CN claimed
WO-2008018843-A1 PROCESS FOR PRODUCING USEFUL SALTS FORM OF BIPHENYL-TETRAZOLE COMPOUNDS ULKAR KIMYA SANAYI VE TICARET AS (TR) 2008-02-14 WO claimed
EP-0720657-B1 BIOLOGICALLY RELEVANT METHODS FOR THE RAPID DETERMINATION OF STERILITY 3M INNOVATIVE PROPERTIES CO (US) 2007-08-15 EP claimed
WO-2006097121-A1 METHOD FOR PRODUCING BIPHENYL-TETRAZOLE COMPOUNDS ULKAR KIMYA SANAYII VE TICARET A.S. (TR) 2006-09-21 WO claimed
WO-2006098705-A1 PROCESS FOR PRODUCING BIPHENYL-TETRAZOLE COMPOUNDS ULKAR KIMYA SANAYII VE TICARET AS (TR) 2006-09-21 WO claimed
US-20050059720-A1 Medicinal compositions for the prevention or treatment of cardiac failure SANKYO COMPANY, LIMITED (JP) 2005-03-17 US claimed
US-20030181500-A1 Medicinal compositions for the prevention or treatment of cardiac failure SANKYO COMPANY, LIMITED (JP) 2003-09-25 US claimed
EP-0734398-B1 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORP (US) 2002-02-27 EP claimed
EP-0842424-B1 PROCESS FOR DETERMINING THE EFFECTIVENESS AND TOLERANCE OF A XENOGENIC SUBSTANCE ADMINISTERED TO AN ORGANISM LAUK CHRISTIANE (DE) 1999-11-03 EP claimed
US-4662905-A REACTION PRODUCT OF COPPER SALT AND AN IMIDAZOLE, PYRAZOLE, TRIAZOLE, OR TETRAZOLE Itaru Todoriki, Director of Agency of Industrial Science and Technology (JP) 1987-05-05 US claimed
JP-10081632-A None JP disclosed
US-4662905-A REACTION PRODUCT OF COPPER SALT AND AN IMIDAZOLE, PYRAZOLE, TRIAZOLE, OR TETRAZOLE Itaru Todoriki, Director of Agency of Industrial Science and Technology (JP) 1987-05-05 US disclosed
EP-0172427-A2 Process for production of vinyl chloride polymer Shin-Etsu Chemical Co., Ltd. (JP) 1986-02-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059720-A1 Medicinal compositions for the prevention or treatment of cardiac failure HMGCR, AGTR2, ACE LMNA 702/4885HSD17B10 1340/4885ALDH1A1 4144/4885
US-20030181500-A1 Medicinal compositions for the prevention or treatment of cardiac failure HMGCR, AGTR2, ACE LMNA 702/4885HSD17B10 1340/4885ALDH1A1 4144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.